Regal Asian Investments Limited: Portfolio Update Amid Biotech Setback

Regal Asian Investments Limited (ASX: RG8) has provided an update following disappointing trial results from Opthea Limited (OPT), a biopharmaceutical company in its portfolio. OPT, listed on both the ASX and Nasdaq, announced negative topline results from the first of two Phase 3 clinical trials for its lead eye therapy, OPT-302. Consequently, trading of OPT shares remains suspended until 31 March 2025. In response, RG8’s investment manager has revalued its OPT holding to AU$ 20 cents per share, factoring in the trial results and the potential for a more favourable outcome from the second trial. As of 24 March 2025, RG8’s post-tax net tangible asset (NTA) per share stood at AU$2.19. RG8 is an actively managed fund with a concentrated portfolio of long and short positions in Asian securities, managed by Regal Funds Management since 2022 using a bottom-up investment approach rooted in fundamental analysis.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com